Investigational monoclonal antibodies in early development for psoriatic arthritis: beyond the biosimilars

References

• Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021 Aug 1;157(8):940–946. doi: 10.1001/jamadermatol.2021.2007
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251–265.e19. doi: 10.1016/j.jaad.2018.06.027
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78. doi: 10.1016/0049-0172(73)90035-8
   PubMedGoogle Scholar
• Ritchlin CT, Colbert RA, Gladman DD, et al. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957–970. doi: 10.1056/NEJMra1505557
   PubMed Web of Science ®Google Scholar
• Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii37–9. discussion ii40-1. doi: 10.1136/ard.2004.030775
   PubMedGoogle Scholar
• Li Q, Chandran V, Tsoi L, et al. Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). Sci Rep. 2020 Mar 18;10(1):4925. doi: 10.1038/s41598-020-61981-5
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Pellett F, et al. Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. Ann Rheum Dis. 2012 Aug;71(8):1361–1365. doi: 10.1136/annrheumdis-2012-201308
   PubMed Web of Science ®Google Scholar
• Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022 Jun;18(6):311–325. doi: 10.1038/s41584-022-00776-6
   PubMed Web of Science ®Google Scholar
• Okada Y, Han B, Tsoi LC, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014 Aug 7;95(2):162–172. doi: 10.1016/j.ajhg.2014.07.002
   PubMed Web of Science ®Google Scholar
• Winchester R, O’Rielly D, Rahman P. Genetics of psoriatic arthritis. In: Gladman D FitzGerald O, editors. Oxford textbook of psoriatic arthritis. Oxford (UK): Oxford University Press; 2019. p. 57–67. doi: 10.1093/med/9780198737582.003.0006
   Google Scholar
• Rahmati S, Tsoi L, O’Rielly D, et al. Complexities in genetics of psoriatic arthritis. Curr Rheumatol Rep. 2020 Mar 12;22(4):10. doi: 10.1007/s11926-020-0886-x
   PubMed Web of Science ®Google Scholar
• McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all. Curr Opin Rheumatol. 2009 Jul;21(4):340–347. doi: 10.1097/BOR.0b013e32832c6ab9
   PubMed Web of Science ®Google Scholar
• Lyu X, Chen J, Gao X, et al. Emerging story of gut dysbiosis in spondyloarthropathy: from gastrointestinal inflammation to spondyloarthritis. Front Cell Infect Microbiol. 2022;12:973563. doi: 10.3389/fcimb.2022.973563
   PubMed Web of Science ®Google Scholar
• Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis & rheumat. 2015 Jan;67(1):128–139. doi: 10.1002/art.38892
   PubMed Web of Science ®Google Scholar
• Boix-Amorós A, Badri MH, Manasson J, et al. Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin. Ann Rheum Dis. 2022 [May 2023];ard-2022–223389. doi:10.1136/ard-2022-223389
   Web of Science ®Google Scholar
• Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol. 2010 Dec;6(12):698–706. doi: 10.1038/nrendo.2010.190
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007 May;212(1):47–55. doi: 10.1002/path.2153
   PubMed Web of Science ®Google Scholar
• Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol. 2011 Oct 18;7(12):700–707.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009;11(2):221. doi: 10.1186/ar2642
   PubMed Web of Science ®Google Scholar
• Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015 Jun;74(6):1045–1050. doi: 10.1136/annrheumdis-2013-204858
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–545. doi: 10.4161/mabs.3.6.17815
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskeletal Care. 2022 Nov;20 Suppl 1(Suppl 1):S12–S21. doi: 10.1002/msc.1694
   PubMedGoogle Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126–1136. doi: 10.1016/S0140-6736(20)30263-4
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022 Feb;81(2):225–231. doi: 10.1136/annrheumdis-2021-221019
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137–1146. doi: 10.1016/S0140-6736(15)61134-5
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of Ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018 Mar;45(3):367–377. doi: 10.3899/jrheum.170429
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi: 10.3389/fimmu.2020.01894
   PubMed Web of Science ®Google Scholar
• Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021 Feb;80(2):185–193. doi: 10.1136/annrheumdis-2019-216835
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020–1026. doi: 10.1136/annrheumdis-2013-205056
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016 Jan;12(1):25–36. doi: 10.1038/nrrheum.2015.167
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525–1536. doi: 10.1056/NEJMoa1615977
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for psoriatic arthritis. N Engl J Med. 2021 Apr 1;384(13):1227–1239. doi: 10.1056/NEJMoa2022516
   PubMed Web of Science ®Google Scholar
• Coates LC, Soriano ER, Corp N, et al. Group for research and Assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465–479. doi: 10.1038/s41584-022-00798-0
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis & Rheumat. 2019 Jan;71(1):5–32. doi: 10.1002/art.40726
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members. Immunity. 2011 Feb 25;34(2):149–162. doi: 10.1016/j.immuni.2011.02.012
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009 Aug;9(8):556–567. doi: 10.1038/nri2586
   PubMed Web of Science ®Google Scholar
• Kolbinger F, Loesche C, Valentin MA, et al. β-defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017 Mar;139(3):923–932.e8. doi: 10.1016/j.jaci.2016.06.038
   PubMed Web of Science ®Google Scholar
• Bimzlex (bimekizumab) injection [product monograph]. Oakville (ON) Canada: UCB Canada Inc; 2022 Feb.
   Google Scholar
• McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023 Jan 7;401(10370):25–37. doi: 10.1016/S0140-6736(22)02302-9
   PubMed Web of Science ®Google Scholar
• Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023 Jan 7;401(10370):38–48. doi: 10.1016/S0140-6736(22)02303-0
   PubMed Web of Science ®Google Scholar
• Škrlec K, Štrukelj B, Berlec A. Non-immunoglobulin scaffolds: a focus on their targets. Trends Biotechnol. 2015 Jul;33(7):408–418. doi: 10.1016/j.tibtech.2015.03.012
   PubMed Web of Science ®Google Scholar
• Behrens F, Taylor PC, Wetzel D, et al. OP0258 IZOKIBEP (ABY-035) in patients with active psoriatic arthritis – 16-week results from a phase 2 study. Ann Rheumatic Dis. 2022 Jun;81(Suppl 1):170–171. doi: 10.1136/annrheumdis-2022-eular.536
   Google Scholar
• Korotaeva T, Gaydukova I, Mazurov V, et al. POS1043. Netakimab reduces psoriatic arthritis activity in patients with or without axial disease: subanalysis of the patera study. Ann Rheum Dis. 2021 Jun;80(Suppl 1):796–797. doi: 10.1136/annrheumdis-2021-eular.1555
   PubMedGoogle Scholar
• Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95–102. doi: 10.1016/j.jaad.2022.01.005
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276–288. doi: 10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586–1596. doi: 10.1056/NEJMoa1010858
   PubMed Web of Science ®Google Scholar
• Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147–1157. doi: 10.1136/annrheumdis-2020-219014
   PubMed Web of Science ®Google Scholar
• Fischer JA, Hueber AJ, Wilson S, et al. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis & Rheumat. 2015 Jan;67(1):51–62. doi: 10.1002/art.38896
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Weinblatt ME, et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-Targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis & rheumat. 2018 Nov;70(11):1778–1789. doi: 10.1002/art.40579
   PubMed Web of Science ®Google Scholar
• Turksen K, Kupper T, Degenstein L, et al. Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5068–5072. doi: 10.1073/pnas.89.11.5068
   PubMed Web of Science ®Google Scholar
• Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6367–6371. doi: 10.1073/pnas.86.16.6367
   PubMed Web of Science ®Google Scholar
• Mizutani H, Ohmoto Y, Mizutani T, et al. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci. 1997 Feb;14(2):145–153. doi: 10.1016/S0923-1811(96)00562-2
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, Berman A, et al. The efficacy and safety of Clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis & Rheumat. 2016 Sep;68(9):2163–2173. doi: 10.1002/art.39700
   PubMed Web of Science ®Google Scholar
• Cohen S, Fiechtner J, Mease P, et al. Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study. Ann Rheum Dis. 2020 Nov;72(suppl 10).
   Google Scholar
• Zhai Y, Moosavi R, Chen M. Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases. Front Immunol. 2021;12:645699. doi: 10.3389/fimmu.2021.645699
   PubMedGoogle Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999 Aug;11(2):141–151. doi: 10.1016/S1074-7613(00)80089-8
   PubMed Web of Science ®Google Scholar
• Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018 Jun;17(6):610–616. doi: 10.1016/j.autrev.2018.01.010
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15;353(11):1114–1123. doi: 10.1056/NEJMoa050524
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011 Apr;63(4):939–948. doi: 10.1002/art.30176
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Scriffignano S, Ciccia F, et al. Clinical characteristics of potential “difficult-to-treat” patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022 Aug;9(4):1193–1201. doi: 10.1007/s40744-022-00461-w
   PubMed Web of Science ®Google Scholar
• Scher JU, Ogdie A, Merola JF, et al. Moving the goalpost toward remission: the case for combination immunomodulatory therapies in psoriatic arthritis. Arthritis & rheumat. 2021 Sep;73(9):1574–1578. doi: 10.1002/art.41765
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb 6;397(10273):487–498. doi: 10.1016/S0140-6736(21)00125-2
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque psoriasis. N Engl J Med. 2021 Jul 8;385(2):142–152. doi: 10.1056/NEJMoa2102383
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017 Sep;76(9):1550–1558. doi: 10.1136/annrheumdis-2016-210724
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023 Jan 17;82(4):515–526. doi: 10.1136/ard-2022-223595
   PubMed Web of Science ®Google Scholar
• Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Jun;81(6):815–822. doi: 10.1136/annrheumdis-2021-221664
   PubMed Web of Science ®Google Scholar
• Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and safety of tyrosine kinase 2/janus kinase 1 inhibitor brepocitinib for active psoriatic arthritis: a phase iib randomized controlled trial. Arthritis & Rheumat. doi: 10.1002/art.42519.
   Google Scholar
• Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001 Sep;145(3):438–445. doi: 10.1046/j.1365-2133.2001.04376.x
   PubMed Web of Science ®Google Scholar
• Gege C. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from vitae pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert Opin Ther Pat. 2017 Jan;27(1):1–8. doi: 10.1080/13543776.2017.1262350
   PubMed Web of Science ®Google Scholar
• Kundu-Raychaudhuri S, Chen YJ, Wulff H, et al. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis–xenograft model. J Autoimmun. 2014 Dec;55:63–72.
   PubMed Web of Science ®Google Scholar